Multiple AMPs such as pexiganan acetate (MSI-78), which is the first commercially developed AMP, hLF1–11, CZEN-002, and novexatin (NP-213) have been approved for clinical use in various infectious diseases as alternatives to antibiotics (Moore, 2003; Gordon et al., 2005; Velden et al., 2009; Fjell et al., 2011). The gene discussed is ADSL; the disease is infectious disease.